Relapse risk of endometrial hyperplasia after treatment with the levonorgestrel-impregnated intrauterine system or oral progestogens.

ABSTRACT:

Objective

To investigate relapse rates after the successful treatment of patients with non-atypical endometrial hyperplasia who were randomised to either a levonorgestrel-impregnated intrauterine system (LNG-IUS; Mirena(®) ) or two regimens of oral medroxyprogesterone acetate (MPA) after primary histological response.

Design

A multicentre randomised trial.

Setting

Ten different outpatient clinics localised in hospitals and seven gynaecological private practices in Norway.

Population

One hundred and fifty-three women aged 30-70 years with low- or medium-risk endometrial hyperplasia met the inclusion criteria, and 153 completed the therapy.

Methods

Patients were randomly assigned to one of the following three treatment arms: LNG-IUS; 10 mg of oral MPA admi

SUBMITTER: Orbo A 

PROVIDER: S-EPMC5215722 | biostudies-literature | 2016 Aug

REPOSITORIES: biostudies-literature